We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+6.49%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$5.2B
AUM Growth
-$978M
Cap. Flow
-$700M
Cap. Flow %
-13.47%
Top 10 Hldgs %
44.11%
Holding
176
New
13
Increased
49
Reduced
69
Closed
15

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$22.9M
2
BRKR icon
Bruker
BRKR
+$21.3M
3
AMGN icon
Amgen
AMGN
+$19M
4
EHC icon
Encompass Health
EHC
+$16.6M
5
THC icon
Tenet Healthcare
THC
+$15.6M

Top Sells

Rank Stock Value
1
OPCH icon
Option Care Health
OPCH
+$51.8M
2
EPIX
ESSA Pharma
EPIX
+$47.8M
3
EXAS
Exact Sciences
EXAS
+$47M
4
CDNA icon
CareDx
CDNA
+$43.1M
5
EXEL icon
Exelixis
EXEL
+$41.5M

Sector Composition

Rank Sector Weight
1 Healthcare 99.84%
2 Industrials 0.04%
3 Communication Services 0.03%
4 Technology 0.01%
5 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARGX icon
1
argenx
ARGX
$53.8B
$365M 7.02%
593,184
-39,645
-6% -$23.2M
IONS icon
2
Ionis Pharmaceuticals
IONS
$8.99B
$275M 5.3%
7,868,700
-5,700
-0.1% -$213K
NBIX icon
3
Neurocrine Biosciences
NBIX
$17.2B
$248M 4.78%
1,820,000
-43,800
-2% -$5.42M
ISRG icon
4
Intuitive Surgical
ISRG
$122B
$242M 4.67%
464,377
-32,398
-7% -$16.9M
ITCI
5
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$204M 3.92%
2,440,240
-45,387
-2% -$3.73M
VRTX icon
6
Vertex Pharmaceuticals
VRTX
$123B
$196M 3.78%
487,434
-83,972
-15% -$38.9M
RVMD icon
7
Revolution Medicines
RVMD
$39.6B
$192M 3.69%
4,386,900
-484,460
-10% -$24.4M
ABT icon
8
Abbott
ABT
$175B
$191M 3.68%
1,688,660
-55,278
-3% -$6.39M
BSX icon
9
Boston Scientific
BSX
$65.4B
$191M 3.67%
2,135,295
-317,502
-13% -$27.9M
SYK icon
10
Stryker
SYK
$123B
$187M 3.6%
520,026
-6,581
-1% -$2.44M
ALNY icon
11
Alnylam Pharmaceuticals
ALNY
$35.7B
$181M 3.49%
770,268
-38,827
-5% -$10.2M
INCY icon
12
Incyte
INCY
$23.4B
$149M 2.87%
2,157,478
+6,927
+0.3% +$494K
AGIO icon
13
Agios Pharmaceuticals
AGIO
$2.36B
$116M 2.22%
3,515,150
-220,765
-6% -$10.4M
SRRK icon
14
Scholar Rock
SRRK
$6.33B
$109M 2.09%
2,510,690
+349,487
+16% +$11.4M
PODD icon
15
Insulet
PODD
$11.4B
$84M 1.62%
321,917
-99,562
-24% -$25.1M
MDT icon
16
Medtronic
MDT
$106B
$83.3M 1.6%
1,042,948
+34,315
+3% +$2.97M
EW icon
17
Edwards Lifesciences
EW
$49.4B
$81.3M 1.56%
1,097,848
-36,228
-3% -$2.54M
DXCM icon
18
DexCom
DXCM
$29.6B
$81.3M 1.56%
1,045,044
+28,006
+3% +$2.07M
UNH icon
19
UnitedHealth
UNH
$387B
$80.8M 1.56%
159,713
-65,837
-29% -$37.4M
CLDX icon
20
Celldex Therapeutics
CLDX
$2.77B
$77.6M 1.49%
3,071,615
– –
BDX icon
21
Becton Dickinson
BDX
$43.6B
$76.6M 1.47%
337,548
-85
-0% -$19.6K
BHVN icon
22
Biohaven
BHVN
$2.32B
$76.2M 1.47%
2,040,853
– –
MRNA icon
23
Moderna
MRNA
$24.5B
$66.6M 1.28%
1,600,877
+41
+0% +$1.96K
PEN icon
24
Penumbra
PEN
$12.5B
$56.5M 1.09%
238,053
-34,630
-13% -$7.87M
WVE icon
25
Wave Life Sciences
WVE
$1.12B
$50.6M 0.97%
4,094,458
– –
1
2 3 4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q4 2024 Portfolio in Review

As of Q4 2024, Bellevue Group held 176 positions worth $5.2B, down 16% from $6.17B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Bellevue Group withdrew a net $700M in Q4 2024, closing 15 positions and reducing 69 holdings. Its most notable exit was Option Care Health, an estimated $51.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Industrials and Communication Services.

Against the trend, Bellevue Group opened a new position in Bruker worth $21.1M.

  • Bellevue Group's largest Q4 2024 buy was Bruker: 359,588 shares worth $21.1M.
  • Bellevue Group added most to Merck in Q4 2024, an estimated $22.9M increase.
  • Bellevue Group's biggest Q4 2024 reduction was Exact Sciences, cutting an estimated $47M.
  • Bellevue Group fully exited Option Care Health in Q4 2024, selling an estimated $51.8M.
  • Bellevue Group's ten largest holdings make up 44% of its $5.2B portfolio in Q4 2024.
  • Bellevue Group opened 13 new positions and closed 15 in Q4 2024.
  • Bellevue Group's portfolio value fell 16% quarter-over-quarter to $5.2B.

Based on Bellevue Group's 13F filing for Q4 2024, filed 14 Feb 2025.